- Home
- SB vs JANX Comparison
SB vs JANX Comparison
Compare SB & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SB | JANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Monaco | United States |
| Employees | 1107 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.7M | 847.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SB | JANX |
|---|---|---|
| Price | $6.89 | $14.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $6.00 | ★ $47.00 |
| AVG Volume (30 Days) | 420.0K | ★ 865.2K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $3.47 | N/A |
| Revenue Next Year | $3.61 | N/A |
| P/E Ratio | $16.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.56 | $12.12 |
| 52 Week High | $7.38 | $35.34 |
Technical Indicators
Market Signals| Indicator | SB | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 49.07 |
| Support Level | $6.43 | $13.88 |
| Resistance Level | $7.38 | $14.57 |
| Average True Range (ATR) | 0.24 | 0.56 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 35.26 | 66.20 |
Price Performance
Historical ComparisonAbout SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain, and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services. The company generates almost all of its revenue from Time Charters.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.